Literature DB >> 19037230

Hypertension and heart failure: a dysfunction of systole, diastole or both?

G W Yip1, J W H Fung, Y-T Tan, J E Sanderson.   

Abstract

The pathological myocardial hypertrophy associated with hypertension contains the seed for further maladaptive development. Increased myocardial oxygen consumption, impaired epicardial coronary perfusion, ventricular fibrosis and remodelling, abnormalities in long-axis function and torsion, cause, to a varying degree, a mixture of systolic and diastolic abnormalities. In addition, chronotropic incompetence and peripheral factors such as lack of vasodilator reserve and reduced arterial compliance further affect cardiac output particularly on exercise. Many of these factors are common to hypertensive heart failure with a normal ejection fraction as well as systolic heart failure. There is increasing evidence that these apparently separate phenotypes are part of a spectrum of heart failure differing only in the degree of ventricular remodelling and volume changes. Furthermore, dichotomizing heart failure into systolic and diastolic clinical entities has led to a paucity of clinical trials of therapies for heart failure with a normal ejection fraction. Therapies aimed at reversing myocardial fibrosis, and targets outside the heart such as enhancing vasodilator reserve and improving chronotropic incompetence deserve further study and may improve the exercise capacity of hypertensive heart failure patients. Hypertension heart disease with heart failure is simply not a dysfunction of systole and diastole. Other peripheral factors including heart rate and vasodilator response with exercise may deserve equal attention in an attempt to develop more effective treatments for this disorder.

Entities:  

Mesh:

Year:  2008        PMID: 19037230     DOI: 10.1038/jhh.2008.141

Source DB:  PubMed          Journal:  J Hum Hypertens        ISSN: 0950-9240            Impact factor:   3.012


  15 in total

1.  Fropofol decreases force development in cardiac muscle.

Authors:  Xianfeng Ren; William Schmidt; Yiyuan Huang; Haisong Lu; Wenjie Liu; Weiming Bu; Roderic Eckenhoff; Anthony Cammarato; Wei Dong Gao
Journal:  FASEB J       Date:  2018-03-09       Impact factor: 5.191

2.  Influence of age and gender on Doppler index of diastolic function in Chinese hypertensive patients.

Authors:  D Zhu; B Chen; X Feng; Z Li; W Li; Y Nie; X Ma; Y Yu; W Gao
Journal:  Ir J Med Sci       Date:  2014-07-22       Impact factor: 1.568

3.  Excision of titin's cardiac PEVK spring element abolishes PKCalpha-induced increases in myocardial stiffness.

Authors:  Bryan D Hudson; Carlos G Hidalgo; Michael Gotthardt; Henk L Granzier
Journal:  J Mol Cell Cardiol       Date:  2009-12-21       Impact factor: 5.000

4.  Long-term follow-up of participants with heart failure in the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT).

Authors:  Linda B Piller; Sarah Baraniuk; Lara M Simpson; William C Cushman; Barry M Massie; Paula T Einhorn; Suzanne Oparil; Charles E Ford; James F Graumlich; Richard A Dart; David C Parish; Tamrat M Retta; Aloysius B Cuyjet; Syed Z Jafri; Curt D Furberg; Mohammad G Saklayen; Udho Thadani; Jeffrey L Probstfield; Barry R Davis
Journal:  Circulation       Date:  2011-10-03       Impact factor: 29.690

5.  Cardiac HDAC6 catalytic activity is induced in response to chronic hypertension.

Authors:  Douglas D Lemon; Todd R Horn; Maria A Cavasin; Mark Y Jeong; Kurt W Haubold; Carlin S Long; David C Irwin; Sylvia A McCune; Eunhee Chung; Leslie A Leinwand; Timothy A McKinsey
Journal:  J Mol Cell Cardiol       Date:  2011-04-23       Impact factor: 5.000

6.  Cellular FLICE-like inhibitory protein protects against cardiac hypertrophy by blocking ASK1/p38 signaling in mice.

Authors:  Ying Huang; Lianpin Wu; Jian Wu; Yumei Li; Lili Hou
Journal:  Mol Cell Biochem       Date:  2014-08-03       Impact factor: 3.396

7.  Aldehyde dehydrogenase 2 as a potential protective factor for renal insufficiency in Japanese subjects with heart failure: a pilot study.

Authors:  K Morita; K Oniki; H Miyazaki; J Saruwatari; Y Ogata; M Mizobe; M Yamamuro; S Hokimoto; H Ogawa; K Nakagawa
Journal:  J Hum Hypertens       Date:  2013-09-26       Impact factor: 3.012

8.  Bone marrow mononuclear cells induce beneficial remodeling and reduce diastolic dysfunction in the left ventricle of hypertensive SS/MCWi rats.

Authors:  Sarah J Parker; Daniela N Didier; Jamie R Karcher; Timothy J Stodola; Bradley Endres; Andrew S Greene
Journal:  Physiol Genomics       Date:  2012-07-31       Impact factor: 3.107

9.  HIF-driven SF3B1 induces KHK-C to enforce fructolysis and heart disease.

Authors:  Peter Mirtschink; Jaya Krishnan; Fiona Grimm; Alexandre Sarre; Manuel Hörl; Melis Kayikci; Niklaus Fankhauser; Yann Christinat; Cédric Cortijo; Owen Feehan; Ana Vukolic; Samuel Sossalla; Sebastian N Stehr; Jernej Ule; Nicola Zamboni; Thierry Pedrazzini; Wilhelm Krek
Journal:  Nature       Date:  2015-06-17       Impact factor: 49.962

10.  Histone deacetylase inhibitor, CG200745, attenuates cardiac hypertrophy and fibrosis in DOCA-induced hypertensive rats.

Authors:  Eunjo Lee; Min-Ji Song; Hae-Ahm Lee; Seol-Hee Kang; Mina Kim; Eun Kyoung Yang; Do Young Lee; Seonggu Ro; Joong Myung Cho; Inkyeom Kim
Journal:  Korean J Physiol Pharmacol       Date:  2016-08-26       Impact factor: 2.016

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.